Press release
Pegcetacoplan is approved by the FDA for patients aged 12 and up with rare kidney diseases C3G and primary IC-MPGN
Rare Kidney Diseases
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72615
Market Overview
The global rare kidney diseases market was valued at USD 1.25 billion in 2024 and is projected to reach USD 3.95 billion by 2034, expanding at a CAGR of 12.3% during the forecast period.
Key Highlights:
• Market Size 2024: USD 1.25 billion
• Forecast 2034: USD 3.95 billion
• CAGR (2024-2034): 12.3%
• Growth Drivers: Increasing awareness of rare diseases, government incentives for orphan drug development, and advancements in genetic testing.
• Challenges: High treatment costs, delayed diagnosis, and limited patient pools for clinical trials.
• Leading Players: Alexion Pharmaceuticals, Sanofi Genzyme, AstraZeneca, Bayer, Otsuka Holdings, Vertex Pharmaceuticals, Novartis, and Travere Therapeutics.
The market's growth trajectory is shaped by the urgent need for novel therapies, patient advocacy group involvement, and growing research into gene and cell-based treatments for nephrology.
Segmentation Analysis
By Disease Type:
• Alport Syndrome
• Fabry Disease
• Focal Segmental Glomerulosclerosis (FSGS)
• Atypical Hemolytic Uremic Syndrome (aHUS)
• Other rare kidney conditions
By Therapy Type:
• Enzyme replacement therapies (ERT)
• Gene therapies
• Biologics and monoclonal antibodies
• Small molecules
• Supportive therapies (dialysis, transplantation-related treatments)
By Diagnostic Technology:
• Genetic testing
• Biopsy techniques
• Imaging (MRI, ultrasound, CT)
• Biomarker assays
By End-User:
• Hospitals & clinics
• Specialty nephrology centers
• Research institutes
• Pharmaceutical & biotechnology companies
Summary:
The segmentation highlights the rapid evolution of treatment modalities, with gene therapy and biologics gaining traction as leading approaches. While supportive treatments such as dialysis remain essential, the focus is shifting toward disease-modifying and curative solutions.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72615/rare-kidney-diseases-market
Regional Analysis
North America
• Largest market due to advanced healthcare systems, favorable orphan drug legislations (such as the U.S. Orphan Drug Act), and robust biotechnology sector.
• Strong pipeline of clinical trials for Fabry disease and FSGS.
Europe
• Significant share driven by EU orphan drug incentives and well-established nephrology research networks.
• Germany, UK, and France lead in clinical trial participation.
Asia-Pacific
• Fastest-growing region with increasing adoption of genetic testing and expanding rare disease awareness programs.
• China, Japan, and India are key growth markets due to healthcare modernization.
Middle East & Africa
• Growth supported by improved healthcare access and rare disease awareness campaigns in Gulf nations.
• Limited infrastructure remains a challenge, though progress is visible in Saudi Arabia and UAE.
Latin America
• Brazil and Mexico are leading markets, with growing patient advocacy and clinical trial involvement.
• Limited access to advanced therapies slows adoption.
Summary:
While North America dominates, Asia-Pacific is expected to record the highest CAGR (13%+), driven by expanding diagnostic capabilities and government support for rare disease initiatives.
Market Dynamics
Key Growth Drivers:
• Rising prevalence of chronic and rare kidney disorders.
• Expanding pipeline of orphan drugs in nephrology.
• Increased patient advocacy and awareness programs.
• Favorable regulatory support encouraging R&D.
Key Challenges:
• High treatment and diagnostic costs.
• Difficulty in conducting large-scale clinical trials due to small patient populations.
• Limited reimbursement in developing economies.
Latest Trends:
• Development of gene therapies and CRISPR-based solutions for rare kidney diseases.
• Increasing collaborations between pharma companies and academic research institutions.
• Expansion of biomarker-based diagnostics to enable early detection.
• Rising focus on patient-centric healthcare and digital registries to track rare kidney disorders.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72615
Competitor Analysis
Major Players in the Market:
• Alexion Pharmaceuticals (AstraZeneca) - Known for therapies targeting aHUS and complement-mediated kidney diseases.
• Sanofi Genzyme - Leading in enzyme replacement therapies for Fabry disease.
• Otsuka Holdings - Active in nephrology with a strong portfolio for polycystic kidney disease.
• Bayer AG - Investing in biologics and precision medicines for rare conditions.
• Vertex Pharmaceuticals - Developing therapies targeting genetic kidney diseases.
• Travere Therapeutics - Focused on innovative treatments for FSGS and IgA nephropathy.
• Novartis AG - Engaged in biologics and gene therapy R&D.
Competitive Summary:
The competitive landscape is shaped by intense R&D activity, strategic licensing, and mergers & acquisitions. Companies are prioritizing genetic and molecular research platforms to create disease-modifying treatments. Partnerships with patient advocacy groups and nephrology institutes are also critical in driving awareness and clinical adoption.
Conclusion
The Rare Kidney Diseases Market is evolving rapidly, moving from symptomatic management to precision medicine and targeted therapies. With a projected market size of USD 3.95 billion by 2034, the sector represents an expanding opportunity for biopharmaceutical innovation.
Key Takeaways:
• Market to grow at 12.3% CAGR (2024-2034).
• Strong opportunities in gene therapy, enzyme replacement therapy, and biomarker-based diagnostics.
• North America leads the market, but Asia-Pacific will be the fastest-growing region.
• Key players are actively pursuing strategic partnerships and clinical expansion.
• Patient-centric approaches and digital tools will further enhance diagnosis and treatment.
As precision therapies and genetic research advance, the rare kidney diseases market is set to transform patient care, offering new hope to populations that previously faced limited options.
This report is also available in the following languages : Japanese (希少腎臓疾患市場), Korean (희귀 신장 질환 시장), Chinese (罕见肾脏疾病市场), French (Marché des maladies rénales rares), German (Markt für seltene Nierenerkrankungen), and Italian (Mercato delle malattie renali rare), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72615/rare-kidney-diseases-market#request-a-sample
Our More Reports:
Molecular Switches Market
https://exactitudeconsultancy.com/reports/73708/molecular-switches-market
Manufacturing Execution System Market
https://exactitudeconsultancy.com/reports/73709/manufacturing-execution-system-market
Women's Digital Health Market
https://exactitudeconsultancy.com/reports/73710/women-s-digital-health-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pegcetacoplan is approved by the FDA for patients aged 12 and up with rare kidney diseases C3G and primary IC-MPGN here
News-ID: 4202330 • Views: …
More Releases from Exactitude Consultancy
NRAS, HRAS, and KRAS Market Targeting Key Oncogenes in the Era of Precision Medi …
Introduction
The RAS gene family - comprising NRAS, HRAS, and KRAS - plays a pivotal role in regulating cell proliferation, differentiation, and survival. Mutations in these oncogenes are among the most common drivers of cancer, particularly in lung, colorectal, pancreatic, and melanoma cases. Of the three, KRAS mutations are the most prevalent, accounting for a significant percentage of cancers worldwide, while NRAS and HRAS mutations, though less common, are equally critical…
Current study on mesenchymal stem cell exosome therapy's potential to reverse no …
The global Exosome Therapy Market is emerging as a transformative frontier in regenerative medicine, precision diagnostics, and targeted drug delivery. Exosomes, nanosized extracellular vesicles secreted by cells, are now recognized as powerful mediators of intercellular communication, capable of influencing tissue regeneration, immune modulation, and disease progression. Over the past decade, interest in exosome-based therapies has grown rapidly, with applications spanning oncology, neurology, cardiology, dermatology, and orthopedics. By 2034, the exosome…
A 'Silver Lining' for Ascending Thoracic Aortic Aneurysms
Introduction
A thoracic aortic aneurysm (TAA) is a serious cardiovascular condition characterized by abnormal dilation of the aorta within the chest, which can lead to life-threatening complications if left untreated, including dissection and rupture. Risk factors include hypertension, atherosclerosis, connective tissue disorders, and genetic syndromes such as Marfan and Loeys-Dietz.
Although TAAs are relatively rare compared to abdominal aortic aneurysms, they carry high morbidity and mortality risks. Early detection through imaging and…
For the targeted treatment of localized prostate cancer, photodynamic therapy
Introduction
Photodynamic therapy (PDT) is an innovative, minimally invasive treatment that combines photosensitizing agents, oxygen, and light to selectively destroy abnormal or cancerous cells. Originally developed for dermatological conditions, PDT has rapidly expanded into oncology, ophthalmology, and infectious diseases, offering a targeted therapy with fewer side effects compared to chemotherapy and radiation.
The rising prevalence of cancer, non-melanoma skin disorders, and antimicrobial resistance has made PDT an increasingly attractive therapeutic option. Over…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
